Positive Phase II study results announced

Novagali Pharma has announced positive results from its Phase II trial of the preservative-free cationic emulsion, Catioprost.

Related Content:

Articles

Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives

Investigators find genetic factors may influence diabetic eye disease

The rationale for enabling nurses to inject dexamethasone implants